American biotech startup CREATE Medicines inks license agreement with Australia’s Monash University

Broadens CREATE's delivery toolkit with access to Monash's novel LNP chemistries and next-generation targeting technologies

CREATE Medicines, Inc., a US-based clinical-stage biotechnology company pioneering in vivo immune programming, has announced a strategic research collaboration with Australia's Monash University and its world-leading Monash Institute of Pharmaceutical Sciences (MIPS).

The partnership broadens CREATE's portfolio by accessing Monash's advanced lipid nanoparticle (LNP) technology including proprietary binders and chemistry, strengthening its leadership in developing best-in-class targeted in vivo therapies.

Targeted delivery remains one of the primary challenges in realising the full therapeutic potential of in vivo cell therapies, requiring increasingly precise control over which immune cells receive therapeutic payloads.

Together, CREATE and MIPS will jointly advance targeted Chimeric Antigen Receptor (CAR) therapy, with the goal of enabling precise, cell-type-specific in vivo delivery of CAR payloads utilising the targeted LNP technology.

Under the agreement, CREATE receives a worldwide exclusive license to all intellectual property, arising from the collaboration, together with the right to develop and commercialise CAR products directed to designated CAR targets. In turn, MIPS will receive research funding and downstream milestone and royalty payments.